Associate Professor Richard Haynes
- MRC Population Health Research Unit Programme Leader: Randomised Trials in Cardiovascular and Metabolic Disease
- MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis
Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he is now Programme Leader in the MRC Population Health Research Unit for the programme in Randomised Trials in Cardiovascular and Metabolic Disease
Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.
3C Study Collaborative Group None., (2018), Am J Transplant, 18, 1424 - 1434
PCSK9 inhibition: ready for prime time in CKD?
Mafham M. and Haynes R., (2018), Kidney Int, 93, 1267 - 1269
Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis.
Marthi A. et al, (2018), J Am Soc Nephrol
Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy.
Storey BC. et al, (2018), Kidney Int, 93, 1165 - 1174
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.
Storey BC. et al, (2018), Kidney Int, 93, 1000 - 1007